Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Receivables - Other: 2020-2024

  • Cellebrite DI's Receivables - Other fell 8.78% to $81.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $81.3 million, marking a year-over-year decrease of 8.78%. This contributed to the annual value of $81.3 million for FY2024, which is 8.78% down from last year.
  • According to the latest figures from Q4 2024, Cellebrite DI's Receivables - Other is $81.3 million, which was down 8.78% from $89.2 million recorded in Q4 2023.
  • Cellebrite DI's Receivables - Other's 5-year high stood at $89.2 million during Q4 2023, with a 5-year trough of $33.9 million in Q4 2020.
  • For the 3-year period, Cellebrite DI's Receivables - Other averaged around $84.0 million, with its median value being $81.5 million (2022).
  • As far as peak fluctuations go, Cellebrite DI's Receivables - Other skyrocketed by 113.13% in 2021, and later dropped by 8.78% in 2024.
  • Over the past 5 years, Cellebrite DI's Receivables - Other (Quarterly) stood at $33.9 million in 2020, then surged by 113.13% to $72.3 million in 2021, then increased by 12.83% to $81.5 million in 2022, then increased by 9.38% to $89.2 million in 2023, then dropped by 8.78% to $81.3 million in 2024.
  • Its Receivables - Other stands at $81.3 million for Q4 2024, versus $89.2 million for Q4 2023 and $81.5 million for Q4 2022.